Stryker Co. (NYSE:SYK) – Equities research analysts at Jefferies Financial Group increased their FY2018 EPS estimates for Stryker in a research report issued on Friday, October 26th. Jefferies Financial Group analyst R. Denhoy now expects that the medical technology company will earn $7.28 per share for the year, up from their prior estimate of $7.23. Jefferies Financial Group also issued estimates for Stryker’s Q1 2019 earnings at $1.91 EPS, Q2 2019 earnings at $1.97 EPS, Q3 2019 earnings at $1.91 EPS, Q4 2019 earnings at $2.24 EPS and FY2021 earnings at $9.52 EPS.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.01. Stryker had a net margin of 9.31% and a return on equity of 28.23%. The business had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.26 billion.

Several other equities analysts have also recently commented on SYK. BMO Capital Markets restated a “hold” rating and issued a $174.00 target price on shares of Stryker in a research report on Thursday, July 12th. Zacks Investment Research cut shares of Stryker from a “buy” rating to a “sell” rating in a research report on Wednesday, July 18th. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Wednesday, July 25th. Royal Bank of Canada restated a “buy” rating and issued a $184.00 target price on shares of Stryker in a research report on Wednesday, July 25th. Finally, Cantor Fitzgerald boosted their target price on shares of Stryker from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, July 25th. Eight analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Stryker has an average rating of “Buy” and an average target price of $180.71.

Shares of Stryker stock opened at $160.38 on Monday. Stryker has a twelve month low of $146.80 and a twelve month high of $179.84. The company has a quick ratio of 1.15, a current ratio of 1.83 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $59.98 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 2.25 and a beta of 0.59.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 31st. Investors of record on Friday, September 28th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 27th. Stryker’s dividend payout ratio (DPR) is presently 28.97%.

In related news, VP Katherine Ann Owen sold 37,866 shares of Stryker stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the sale, the vice president now directly owns 11,367 shares of the company’s stock, valued at approximately $1,896,470.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Glenn S. Boehnlein sold 750 shares of Stryker stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $178.17, for a total transaction of $133,627.50. Following the sale, the chief financial officer now directly owns 2,785 shares in the company, valued at $496,203.45. The disclosure for this sale can be found here. Insiders own 7.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. grew its holdings in shares of Stryker by 1.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 33,035 shares of the medical technology company’s stock valued at $5,870,000 after purchasing an additional 489 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in Stryker by 3.8% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 32,128 shares of the medical technology company’s stock worth $5,707,000 after acquiring an additional 1,170 shares during the last quarter. Trust Co. of Vermont grew its holdings in Stryker by 5.2% during the 3rd quarter. Trust Co. of Vermont now owns 23,500 shares of the medical technology company’s stock worth $4,176,000 after acquiring an additional 1,162 shares during the last quarter. Sawtooth Solutions LLC bought a new stake in Stryker during the 3rd quarter worth approximately $307,000. Finally, Russell Investments Group Ltd. grew its holdings in Stryker by 30.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 194,874 shares of the medical technology company’s stock worth $34,518,000 after acquiring an additional 45,658 shares during the last quarter. 75.23% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Stock Symbol

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.